Directive 65/65/EEC

Directive 65/65/EEC is a significant piece of European Union legislation that was enacted on 26 January 1965. This directive was the first to regulate the pharmaceutical industry in the European Union, setting out the rules for the authorization of medicinal products for human use.

Overview

Directive 65/65/EEC was designed to ensure that all medicinal products, both proprietary and generic, meet the same standards of safety, efficacy, and quality. It established a centralized procedure for the authorization of medicinal products, which is now managed by the European Medicines Agency (EMA).

Key Provisions

The directive introduced several key provisions, including:

• A requirement for all medicinal products to be authorized before they can be placed on the market.
• The establishment of a centralized procedure for the authorization of medicinal products.
• The introduction of a system for the post-marketing surveillance of medicinal products, known as pharmacovigilance.
• The requirement for manufacturers to demonstrate the safety and efficacy of their products through clinical trials.

Impact

Directive 65/65/EEC has had a profound impact on the pharmaceutical industry in the European Union. It has led to the harmonization of standards across member states, ensuring that all medicinal products meet the same high standards of safety, efficacy, and quality. It has also facilitated the free movement of medicinal products within the European Union, promoting competition and innovation in the pharmaceutical industry.

See Also

• European Medicines Agency
• Pharmaceutical industry
• Clinical trials
• Pharmacovigilance

References

   This article is a  stub. You can help WikiMD by expanding it!

   This article is a medical stub. You can help WikiMD by expanding it!